BioXcel Therapeutics, Inc. (BTAI) Reports Q2 Loss, Tops Revenue Estimates

BioXcel Therapeutics, Inc. (BTAI) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of$ 0.76. This compares to loss of $1.83 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 72.37%. A quarter ago, it was expected that this company would post a loss of$ 0.68 per share when it actually produced a loss of $0.87, delivering a surprise of -27.94%. Over the last four quarters, the compan ...